Nivolumab is under clinical development by Ono Pharmaceutical and currently in Phase I for Mantle Cell Lymphoma.

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for T-Cell Lymphomas.

Hair follicles (HF) regenerate throughout adult life, involving a 2-way signaling between epithelial stem cells and its niche. The niche includes mesenchymal cells such as dermal papillae and ...

J Midwifery Womens Health. 2004;49(1) © 2004 Elsevier Science, Inc. Cite this: The Role of Human Papilloma Virus Testing in Cervical Cancer Prevention - Medscape ...

1 University of Rochester School of Medicine and Dentistry, Rochester, NY, United States 2 Department of Imaging Sciences, University of Rochester Medical Center, Rochester, NY, United States ...

Blue Label Telecoms has released its annual results for the year ended 31 May 2024, revealing that Cell C made R22.4 million before-tax loss between 1 June 2023 and 31 May 2024. Blue Label ...

WEDNESDAY, Aug. 28, 2024 (HealthDay News) -- Most patients with basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) have residual tumor at the time of Mohs micrographic surgery (MMS), ...

It’s a key step forward in the long quest to develop a cure for diabetes and a front-runner to finally deliver the sci-fi promise that has enveloped the stem cell field for more than two decades.